This brand name is authorized in France, Tunisia
The drug HYTACAND contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Candesartan
UNII R85M2X0D68 - CANDESARTAN CILEXETIL
|
|
Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity. The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration. |
|
2
Hydrochlorothiazide
UNII 0J48LPH2TH - HYDROCHLOROTHIAZIDE
|
|
Hydrochlorothiazide is a diuretic with antihypertensive properties. It acts by inhibiting the renal tubular re-absorption of sodium and chloride ions, which are excreted with an accompanying volume of water. Potassium excretion is also promoted. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C09DA06 | Candesartan and diuretics | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09D Angiotensin II antagonists, combinations → C09DA Angiotensin II antagonists and diuretics |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: FR | Base de données publique des médicaments | Identifier(s): 64027704, 69025080 |
| Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 4833043, 4833044 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
